Overview

A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors

Status:
Active, not recruiting

Trial end date:
2022-12-06

Target enrollment:

Participant gender:

Summary

The main purpose of this study is to evaluate the safety and tolerability of anti-programmed cell death ligand 1 (PD-L1) checkpoint antibody LY3300054 in participants with advanced refractory solid tumors.

Phase:

Phase 1

Details

Lead Sponsor:

Eli Lilly and Company

Treatments:

Antibodies
Ramucirumab